



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	4	Attorney Docket Number	BSZ-049
-------	---	----	---	------------------------	---------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			
BW	A1	4,078,052	03-07-1978	Papahadjopoulos	
	A2	4,725,442	02-16-1988	Haynes	
	A3	4,871,488	10-03-1989	Mannino, et al.	
	A4	4,874,795	10-17-1989	Yesair	
	A5	4,906,476	03-06-1990	Radhakrishnan	
	A6	4,990,291	02-05-1991	Schoen, et al.	
	A7	5,026,557	06-25-1991	Estis, et al.	
	A8	5,100,591	03-31-1992	Leclef, et al.	
	A9	5,269,979	12-14-1993	Fountain	
	A10	5,409,698	04-25-1995	Anderson, et al.	
	A11	5,571,517	11-05-1996	Yesair	
	A12	5,580,859	12-03-1996	Feigner, et al.	
	A13	5,589,466	12-31-1996	Feigner, et al.	
	A14	5,643,574	07-01-1997	Gould-Fogerite, et al.	
	A15	5,834,015	11-10-1998	Oleske, et al.	
	A16	5,840,707	11-24-1998	Mannino, et al.	
	A17	5,994,318	11-30-1999	Gould-Fogerite, et al.	
	A18	6,120,751	11-19-2000	Unger	
	A19	6,153,217	11-28-2000	Jin, et al.	
	A20	6,340,591	01-22-2002	Margolis, et al.	
	A21	6,403,056	06-11-2002	Unger	
	A22	6,406,713	06-18-2002	Janoff, et al.	
	A23	6,447,800	09-10-2002	Hope	
	A24	6,592,894	07-15-2003	Zarif, et al.	
	A25	2004/0092727	05-13-2004	Jin	
	A26	6,808,720	10-26-2004	Unger	

BW

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)				
BW	A27	FR 2221122 A	10-11-1974	Bayer AG		Abd
BW	A28	WO 96/025942 A1	08-29-1996	Albany Medical College, et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/822,235
				Filing Date	April 9, 2004
				First Named Inventor	Susan Gould-Fogerite
				Art Unit	1653
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	BSZ-049

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
BW	B1	WO 97/030725 A1	08-28-1997	Mannino, et al.		
	B2	WO 00/042989 A2,A3	07-27-2000	Biodelivery Sciences Inc., et al.		
	B3	WO 01/052817 A2,A3	07-26-2001	Biodelivery Sciences Inc., et al.		
	B4	WO 02/044321 A2,A3	06-06-2002	Max Planck Gesellschaft		
	B5	WO 02/097114 A2	12-05-2002	Ribozyme Pharmaceuticals, Inc.		
	B6	WO 04/012709 A1	02-12-2004	Jin		

BW

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST,3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST,16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published,	T ²
BW	B7	Anderson, et al. "Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form." <i>Pharm Res.</i> 2001; 18(3):316-22.	
	B8	Brummelkamp, et al. "A system for stable expression of short interfering RNAs in mammalian cells." <i>Science.</i> 2002 Apr 19; 296(5567):550-3.	
	B9	Burghoorn, et al. "Molecular evaluation of the plasma membrane proton pump from Aspergillus fumigatus." <i>Antimicrob Agents Chemother.</i> 2002 Mar; 46(3):615-24.	
	B10	Couvreur, et al. "Nano- and microparticles for the delivery of polypeptides and proteins." <i>Adv. Drug Delivery Rev.</i> 1993; 10:141-62.	
	B11	Gould-Fogerite, et al. "Chimerasome-mediated gene transfer in vitro and in vivo." <i>Gene.</i> 1989; 84(2):429-38.	
	B12	Gould-Fogerite, et al. "Rotary dialysis: its application to the preparation of large liposomes and large proteoliposomes (protein-lipid vesicles) with high encapsulation efficiency and efficient reconstitution of membrane proteins." <i>Anal Biochem.</i> 1985; 148(1):15-25.	
	B13	Gould-Fogerite, et al. "The reconstitution of biologically active glycoproteins into large liposomes: use as a delivery vehicle to animal cells." <i>Adv Membr Biochem Bioener.</i> 1988; 569-86.	
	B14	Gould-Fogerite, et al. "Liposome preparation and related techniques." <i>Liposome Technology.</i> 2 nd Edition. 1993; 1:67-80.	
	B15	Gould-Fogerite, et al. "Interaction of liposomes with the biological milieu." <i>Liposome Technology.</i> 2 nd Edition. 1993; 3:261-76.	
BW	B16	Gould-Fogerite, et al. "Mucosal and systemic immunization using cochleate and liposome vaccines." <i>J. Liposome Res.</i> 1996; 6(2):357-79.	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/822,235
				Filing Date	April 9, 2004
				First Named Inventor	Susan Gould-Fogerite
				Art Unit	1653
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	BSZ-049

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
BW	C1	Gould-Fogerite, et al. "Targeting immune response induction with cochleate and liposome-based vaccines." <i>Adv Drug Delivery Rev.</i> 1998; 32(3):273-87.				
	C2	Gould-Fogerite, et al. "Cochleates for induction of mucosal and systemic immune responses." <i>Meth Molec Med.</i> 1999; 42:179-96.				
	C3	Gould-Fogerite, et al. "Cochleate Delivery Vehicles: Applications in Vaccine Delivery." <i>J Liposome Res.</i> 2000; 10(4):339-58.				
	C4	Gould-Fogerite, et al. "Cochleate Delivery Vehicles: Applications to Gene Therapy." 2003 Mar/Apr; 3(2):41-7.				
	C5	Hu, et al. "ERB-B-2/NEU DNA vaccine based immunotherapy." <i>International Congress of Immunology Abstracts.</i> Budapest, Hungary. 1995 Jul 23; 870.				
	C6	Lavelle, et al. "Improved methods for the delivery of liposome-sequestered RNA into eucaryotic cells." <i>Arch Biochem Biophys.</i> 1982; 215(2):486-97.				
	C7	Lichtenberg, et al. "Liposomes: Preparation, characterization and preservation." <i>Meth Biochem Anal.</i> 1988; 33:337-462.				
	C8	Longenecker, et al. "Three dimensional structure of mammalian casein kinase I: Molecular basis for phosphate recognition." <i>J Mol Biol.</i> 1996; 257:618-31.				
	C9	Lu, et al. "siRNA-mediated antitumorigenesis for drug target validation and therapeutics." <i>Curr Opin Mol Ther.</i> 2003 Jun; 5(3):225-34.				
	C10	Mannino, et al. "Liposome mediated gene transfer." <i>Biotechniques.</i> 1988; 6(7):682-90.				
	C11	Mannino, et al. "Liposomes as adjuvants for peptides: Preparation and use of immunogenic peptide-phospholipid complexes." <i>Liposome Technology.</i> 2 nd Edition, 1993; 2:167-84.				
	C12	Mannino, et al. "Lipid matrix-based vaccines for mucosal and systemic immunization." <i>Pharm Biotechnol.</i> 1995; 6:363-87.				
	C13	Mannino, et al. "Antigen cochleate preparations for oral and systemic vaccinations." <i>New Gen Vaccines.</i> 2 nd Edition, 1997; Ch 18, 229-39.				
	C14	Papahadjopoulos, et al. "Cochleate lipid cylinders: Formation by fusion of unilamellar vesicles." <i>Biochim Biophys Acta.</i> 1975; 394(3):483-91.				
	C15	Papahadjopoulos, et al. "The use of lipid vesicles for introducing macromolecules into cells." <i>Prot Tumour Lysosome Funct.</i> 1978; 543-60.				
	C16	Parker, et al. "In vivo and in vitro antiproliferative effects of antisense interleukin 10 oligonucleotides." <i>Meth Enzym: Antisense Tech, Part B.</i> 1999; 314:411-29.				
	C17	Paroo, et al. "Challenges for RNAi in vivo." <i>Trends Biotechnol.</i> 2004 Aug; 22(8):390-4.				
	C18	Sanderson, et al. "Encapsulation of vancomycin and gentamycin with cationic liposomes for inhibition of growth of <i>Staphylococcus epidermidis</i> ." <i>J Drug Target.</i> 1998; 4(3):181-9.				
	C19	Santangelo, et al. "Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis." <i>Antimicrob Agents Chemother.</i> 2000; 2356-60.				
	C20	Sundram, et al. "General and efficient method for the solution- and solid-phase synthesis of vancomycin carboxarnide derivatives." <i>J Org Chem.</i> 1995; 60:1102-3.				
	C21	Wassef, et al. "Liposomes as carriers for vaccines." <i>Immunomethods.</i> 1994; 4(3):217-22.				
	C22	Yamamoto, et al. "Human C-ERB-B-2 mRNA." <i>Genbank.</i> 1995 Mar 30; XP002264793.				

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete If Known</i>	
				Application Number	10/822,235
				Filing Date	April 9, 2004
				First Named Inventor	Susan Gould-Fogerite
				Art Unit	1653
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	BSZ-049

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published,			²
BW	D1	Zarif, et al. "Amphotericin B cochleates as a novel oral delivery system for the treatment of fungal infection." <i>Proceedings of the International Symposium on Controlled Release of Bioactive Materials</i> . Illinois: Controlled Release Society, 1999; 964-5.			
	D2	Zarif, et al. "Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model." <i>Antimicrob Agents Chemother</i> . 2000; 1463-9.			
	D3	Zarif, et al. "Cochleates: New lipid based drug delivery system." <i>J. Liposome Res.</i> 2000; 10(4):523-38.			
	D4	Zarif, et al. "Elongated supramolecular assemblies in drug delivery." <i>J. Controlled Rel.</i> 2002; 81:7-23.			
BW	D5	International Search Report and Written Opinion for Application No. PCT/US2004/011020			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Brian Whiteman/	Date Considered	05/08/2006
--------------------	------------------	-----------------	------------